Page 380 - IJB-10-6

International Journal of Bioprinting 3D-printed NAFLD model

26. Gori M, Simonelli MC, Giannitelli SM, Businaro L, 33. Jamwal R, Barlock BJJP. Nonalcoholic fatty liver disease
Trombetta M, Rainer A. Investigating nonalcoholic fatty (NAFLD) and hepatic cytochrome P450 (CYP) enzymes.
liver disease in a liver-on-a-chip microfluidic device. PLoS Pharmaceuticals (Basel). 2020;13(9):222.
One. 2016;11(7):e0159729. doi: 10.3390/ph13090222
doi: 10.1371/journal.pone.0159729
34. Fierbinteanu-Braticevici C, Baicus C, Tribus L, Papacocea R.
27. Du K, Li S, Li C, et al. Modeling nonalcoholic fatty liver Predictive factors for nonalcoholic steatohepatitis (NASH)
disease on a liver lobule chip with dual blood supply. Acta in patients with nonalcoholic fatty liver disease (NAFLD).
Biomater. 2021;134:228-239. J Gastrointestin Liver Dis. 2011;20(2):153-159.
doi: 10.1016/j.actbio.2021.07.013 doi: 10.15403/jgld.2011.1121.202
28. Kostrzewski T, Maraver P, Ouro-Gnao L, et al. 35. Roth JD, Veidal SS, Fensholdt LKD, et al. Combined
A microphysiological system for studying nonalcoholic obeticholic acid and elafibranor treatment promotes
steatohepatitis. Hepatol Commun. 2020;4(1):77-91. additive liver histological improvements in a diet-induced
doi: 10.1002/hep4.1450 ob/ob mouse model of biopsy-confirmed NASH. Sci Rep.
2019;9(1):9046.
29. Liu J, Zhou Z, Zhang M, Song F, Feng C, Liu H. Simple and
robust 3D bioprinting of full-thickness human skin tissue. doi: 10.1038/s41598-019-45178-z
Bioengineered. 2022;13(4):10087-10097. 36. Boeckmans J, Natale A, Rombaut M, et al. Human hepatic in
doi: 10.1080/21655979.2022.2063651 vitro models reveal distinct anti-NASH potencies of PPAR
agonists. Cell Biol Toxicol. 2021;37:293-311.
30. Li R, Liu J, Ma J, et al. Fibrinogen improves liver function
via promoting cell aggregation and fibronectin assembly in doi: 10.1007/s10565-020-09544-2
hepatic spheroids. Biomaterials. 2022;280:121266. 37. Pingitore P, Sasidharan K, Ekstrand M, Prill S, Lindén D,
doi: 10.1016/j.biomaterials.2021.121266 Romeo S. Human multilineage 3D spheroids as a model of
liver steatosis and fibrosis. Int J Mol Sci. 2019;20(7):1629.
31. Lee JB, Park JS, Shin YM, et al. Implantable vascularized
liver chip for cross‐validation of disease treatment doi: 10.3390/ijms20071629
with animal model. Adv Funct Mater. 2019;29(23): 38. Boeckmans J, Buyl K, Natale A, et al. Elafibranor restricts
1900075. lipogenic and inflammatory responses in a human skin stem
doi: 10.1002/adfm.201900075 cell-derived model of NASH. Pharmacol Res. 2019;144:377-389.
32. Mahjoubin-Tehran M, De Vincentis A, Mikhailidis DP, et al. 39. Banaeiyan AA, Theobald J, Paukštyte J, Wölfl S, Adiels
Non-alcoholic fatty liver disease and steatohepatitis: state of CB, Goksör MJB. Design and fabrication of a scalable
the art on effective therapeutics based on the gold standard liver-lobule-on-a-chip microphysiological platform.
method for diagnosis. Mol Metab. 2021;50:101049. 2017;9(1):015014. doi:10.1088/1758-5090/9/1/015014.
doi: 10.1016/j.molmet.2020.101049 doi: 10.1016/j.phrs.2019.04.016

Volume 10 Issue 6 (2024) 372 doi: 10.36922/ijb.4312